Seralutinib
- Generic Name
- Seralutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C27H27N5O3
- CAS Number
- 1619931-27-9
- Unique Ingredient Identifier
- 3P63ZTE3OY
XOMA Royalty Expands Portfolio to Over 120 Assets, Reports Financial Results for 2024
• XOMA Royalty doubled its portfolio to over 120 royalty assets through five strategic transactions in 2024, strengthening its position as a biotech royalty aggregator.
• The company completed two whole company acquisitions and celebrated FDA approvals for Day One's OJEMDA™ (tovorafenib) and Zevra's MIPLYFFA™ (arimoclomol), generating significant milestone payments.
• Despite reporting a net loss of $13.8 million for 2024, XOMA Royalty received $46.3 million in cash receipts and maintains over $100 million in cash, positioning it for sustainable cashflow from royalties.
Seralutinib Shows Sustained Benefits in PAH Responders Over 72-Week Treatment Period
• Long-term seralutinib treatment demonstrated continued improvement in pulmonary vascular resistance through 72 weeks in PAH patients, with responders showing a median 32% reduction.
• Patients classified as responders exhibited superior outcomes in cardiac output (19.6% vs 1.8%) and mean pulmonary arterial pressure reduction (-11.8% vs -7.7%) compared to the total cohort.
• The treatment maintained a favorable safety profile over the extended period, with common side effects including COVID-19, headache, and epistaxis.
Pipeline for Pulmonary Arterial Hypertension Treatment Expands with 55+ Companies Developing Novel Therapies
• DelveInsight's latest report reveals over 55 companies actively developing 55+ pipeline drugs for Pulmonary Arterial Hypertension treatment, indicating robust research activity in this therapeutic area.
• Breakthrough therapies like Sotatercept by Acceleron Pharma and LIQ861 by Liquidia Technologies are advancing through clinical trials, offering new hope for PAH patients.
• Multiple clinical trials are underway in early 2025, including studies by Actelion, Keros Therapeutics, Insmed Incorporated, and Merck Sharp & Dohme, focusing on novel treatment approaches.
Gossamer Bio to Present Seralutinib Data for PAH Treatment at PVRI 2025 Congress
• Gossamer Bio will showcase multiple analyses of seralutinib from the TORREY Phase 2 open-label extension study at the Pulmonary Vascular Research Institute 2025 Annual Congress.
• The presentations will focus on sustained treatment benefits and biomarker effects of seralutinib in pulmonary arterial hypertension patients.
• The data presentations represent important steps in Gossamer Bio's mission to advance seralutinib as a potential treatment option for pulmonary hypertension.
XOMA Royalty Acquires Pulmokine for $20 Million, Expanding PAH Portfolio with Seralutinib
• XOMA Royalty Corporation acquired Pulmokine for $20 million, gaining rights to seralutinib, a Phase 3 asset for pulmonary arterial hypertension (PAH).
• The acquisition adds seralutinib to XOMA's portfolio, which already includes six commercial royalty assets, enhancing its late-stage pipeline.
• XOMA Royalty stands to gain up to $25 million in milestone payments and a low to mid-single digit royalty on seralutinib's commercial sales.
• Phase 3 study results for seralutinib, co-developed by Gossamer Bio and Chiesi Farmaceutici, are expected in the fourth quarter of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath